BioCentury | Apr 8, 2021
Finance

Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra

...million to advance therapies targeting chromosomal instability to treat cancer. New investors Vida Ventures and Catalio Capital Management...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...Immunai raised $60 million in a series A round led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...Capital, Sands Capital, PFM Health Sciences, Windham Ventures, New Enterprise Associates, Innovatus Capital Partners and Catalio Capital Management.Hung’s...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

...are four firms that debuted with their first biotech venture investments in 2020: Pureos Bioventures, Catalio Capital Management...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...million in a private round co-led by existing investor Apeiron Investment Group and new investor Catalio Capital Management...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

...healthy and disease settings. Novartis Venture Fund, Eli Lilly and Co. (NYSE:LLY), AbbVie Ventures, Invus, Catalio Capital Management...
...raised: $81 millionInvestors: Third Rock, Novartis Venture Fund, Eli Lilly and Co., AbbVie Ventures, Invus, Catalio Capital Management...
BioCentury | Sep 9, 2020
Deals

‘Transformational’ deal with Bayer, $239M series D expand Recursion’s reach into fibrosis

...to biotech mezzanine rounds —Casdin Capital, Catalio Capital Management...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...round, which included new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures and Catalio Capital Management...
...raised: $75.3 million Investors: Section 32, Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, Catalio Capital Management...
Items per page:
1 - 8 of 8
BioCentury | Apr 8, 2021
Finance

Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra

...million to advance therapies targeting chromosomal instability to treat cancer. New investors Vida Ventures and Catalio Capital Management...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...Immunai raised $60 million in a series A round led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...Capital, Sands Capital, PFM Health Sciences, Windham Ventures, New Enterprise Associates, Innovatus Capital Partners and Catalio Capital Management.Hung’s...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

...are four firms that debuted with their first biotech venture investments in 2020: Pureos Bioventures, Catalio Capital Management...
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...million in a private round co-led by existing investor Apeiron Investment Group and new investor Catalio Capital Management...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

...healthy and disease settings. Novartis Venture Fund, Eli Lilly and Co. (NYSE:LLY), AbbVie Ventures, Invus, Catalio Capital Management...
...raised: $81 millionInvestors: Third Rock, Novartis Venture Fund, Eli Lilly and Co., AbbVie Ventures, Invus, Catalio Capital Management...
BioCentury | Sep 9, 2020
Deals

‘Transformational’ deal with Bayer, $239M series D expand Recursion’s reach into fibrosis

...to biotech mezzanine rounds —Casdin Capital, Catalio Capital Management...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...round, which included new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures and Catalio Capital Management...
...raised: $75.3 million Investors: Section 32, Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, Catalio Capital Management...
Items per page:
1 - 8 of 8